Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Article - Media

Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Austin Angelo

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.